General MedicationsINJECTIONStandard
RIVFLOZA
NEDOSIRAN SODIUM
Standard Dose
EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview RIVFLOZA is listed in Drugs@FDA under application 215842 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient NEDOSIRAN SODIUM Form and strength SOLUTION;INJECTION - EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML) Sponsor NOVO Submission history Latest submission status date: 2025-03-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview RIVFLOZA is listed in Drugs@FDA under application 215842 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient NEDOSIRAN SODIUM Form and strength SOLUTION;INJECTION - EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML) Sponsor NOVO Submission history Latest submission status date: 2025-03-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.